VBL Therapeutics presents vascular disruptive agent preclinical data
The first trail results showed that VB-111 was safe and specific and may offer additive effect to chemotherapy. In the trial, the researchers investigated the safety and efficacy
Vertex Pharmaceuticals and Genomics have agreed a four-year extension to their drug discovery partnership in a deal with a potential value exceeding $220m.